Summary
The A Sample, manufactured by Stanford, underwent independent testing to verify its composition and potency. The sample was submitted by Stanford and analyzed by Janoshik Analytical, a laboratory specializing in pharmaceutical quality control. The analysis measured the concentration of Semaglutide at 9.53 mg, with a purity of 99.889%.
The testing process began on 13 December 2023, with the sample received on 21 December 2023, and analysis completed on 4 January 2024. While the results confirm the presence and purity of Semaglutide, scrutiny of manufacturer-submitted samples remains essential to ensure consistency. Independent third-party testing is crucial to validate these findings comprehensively. This report serves as an educational resource to promote harm reduction and informed decision-making.
Detailed Report
Product Overview
- Manufacturer: Stanford
- Product Name: A Sample
- Active Ingredient: Semaglutide
- Batch Number: Not Provided
- Expiration Date: Not Provided
- Delivery Method: Viral Powder
Sample Acquisition and Testing
- Task Number: #37147
- Testing Ordered: 13 December 2023
- Sample Received: 21 December 2023
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: Stanford (Manufacturer)
- Analysis Paid For By: Stanford (Manufacturer)
Testing Results
- Compound Detected: Semaglutide
- Measured Concentration: 9.53 mg
- Purity: 99.889%
Verification Details
Verification URL: https://janoshik.com/tests/37147_BYGDS2TIDP74
Evaluation of Manufacturer-Submitted Testing
This analysis confirms the presence of Semaglutide in the tested sample with a measured purity of 99.889%. However, since Stanford submitted and funded the test, careful evaluation is needed to assess product consistency across different batches. While Janoshik Analytical is recognized for its transparency and rigorous testing protocols, these findings would benefit from independent validation through third-party testing across multiple samples.
Conclusion
The analysis confirms that the A Sample contains Semaglutide at 9.53 mg with a purity of 99.889%. While this batch meets expected quality parameters, the absence of batch details and independent verification highlights the need for further third-party testing to ensure consistency across production. This report is provided to support educational and harm reduction efforts, helping consumers make informed choices regarding peptide-based products.
Disclaimer
This report is published for educational and harm reduction purposes. Manufacturer-submitted testing may involve inherent biases; however, it can still provide useful data when critically assessed alongside third-party or independent results. Readers are encouraged to use this information responsibly.
